

A Turkish SME Consortium Seeks European Partner for AI-Powered Non-Invasive Medical Device Development (Eurostars/Eureka)

Summary

Profile type	Company's country	POD reference
Research & Development Request	Türkiye	RDRTR20260203017
Profile status	Type of partnership	Targeted countries
PUBLISHED	Research and development cooperation agreement	• World
Contact Person	Term of validity	Last update
Enrico FRANZIN	4 Feb 2026 4 Feb 2027	4 Feb 2026

General Information

Short summary

A Turkish consortium is seeking a European partner with expertise in medical device regulatory affairs (CE/MDR certification), clinical validation studies, and/or AI-based health data analytics to collaborate on an innovative wearable medical device project under Eurostars/Eureka programs.

Full description

The RG+ project focuses on developing a next-generation wearable medical device that addresses critical unmet needs in chronic disease management. The consortium has identified significant market opportunities in the growing segments of hypertension monitoring (affecting 1.3 billion people globally) and diabetes management (537 million adults worldwide).

Technical Innovation: The device integrates two breakthrough technologies: (1) PPG technology for continuous blood pressure monitoring with medical-grade accuracy, and (2) Mid-infrared (Mid-IR) spectroscopy for non-invasive glucose measurement. This combination represents a significant technological advancement over current market solutions that typically address only one parameter or require invasive measurements.

AI Integration: Machine learning algorithms process sensor data in real-time to provide accurate measurements, personalized health insights, and predictive analytics for early detection of health anomalies. The AI system continuously improves through clinical validation data.

MR-Conditional Compatibility: Unlike conventional wearables, the device is designed for safe use during MRI procedures, enabling continuous monitoring in diagnostic settings - a unique feature particularly valuable for patients with chronic conditions requiring frequent imaging.

The consortium seeks a European partner to strengthen the project's regulatory pathway, clinical validation, and commercialization strategy to successfully bring this innovative technology to market.

Advantages and innovations

- **Dual-Parameter Monitoring:** First-of-its-kind integration of continuous blood pressure and glucose monitoring in a single wearable device, addressing the needs of patients with comorbid hypertension and diabetes.
- **Novel Sensor Fusion:** Proprietary PPG technology combined with mid-IR spectroscopy represents a technological advancement over existing single-modality solutions.
- **AI-Driven Accuracy:** Machine learning algorithms trained on clinical data enable medical-grade accuracy comparable to traditional invasive methods.
- **MR-Conditional Design:** Unique positioning for hospital and diagnostic environments where conventional electronics cannot be used.
- **Healthcare System Integration:** Real-time wireless data transmission enables remote monitoring and seamless integration with electronic health records.
- **Cost-Effectiveness:** Reduces need for frequent clinic visits and invasive testing, lowering healthcare costs for patients and health systems.

Technical specification or expertise sought

Stage of development

Available for demonstration

IPR Status

IPR applied but not yet granted

IPR Notes

Sustainable Development goals

- **Goal 3: Good Health and Well-being**
- **Goal 17: Partnerships to achieve the Goal**

IPR Notes

Partner Sought

Expected role of the partner

The consortium is seeking ONE strategic European partner with complementary expertise to strengthen the project in key areas. The ideal partner should have experience in at least TWO of the following domains:

PRIORITY 1: Medical Device Regulatory Affairs and Certification (Strongly Preferred)

- Deep expertise in EU Medical Device Regulation (MDR 2017/745) and CE marking processes
- Experience with Class IIa medical device classification and conformity assessment
- Track record of successful medical device certifications in wearables or diagnostics
- Knowledge of FDA 510(k) pathway advantageous for future US market entry

PRIORITY 2: Clinical Validation and Health Data Analytics

- Experience conducting clinical validation studies for medical devices in European healthcare settings
- Expertise in health data collection, management, and analysis compliant with GDPR and medical data regulations
- Capabilities in AI/ML model validation for medical applications
- Access to patient populations for multi-center clinical trials (cardiovascular/diabetes focus)

PRIORITY 3: Market Access and Commercialization

- Established relationships with European healthcare providers, distributors, or health systems
- Experience in medical device commercialization and market entry strategies
- Understanding of European reimbursement pathways for digital health solutions

Type of partnership

Research and development cooperation agreement

Type and size of the partner

- University
- SME 50 - 249
- SME <=10
- SME 11-49
- R&D Institution

Call Details

Framework program

Eureka

Call title and identifier

Eurostars / Eureka Network - Cut-off September 2026

Submission and evaluation scheme

Anticipated project budget

Coordinator required

No

Deadline for EoI

11 Sep 2026

Deadline of the call

15 Sep 2026

Project duration in weeks

Web link to the call

144

Project title and acronym

Dissemination

Technology keywords

• 09003 - Electronic measurement systems

Market keywords

• 05004001 - Electromedical and medical equipment
• 05003001 - Therapeutic services

Targeted countries

Sector groups involved

• World**• Health**